PHESGO Drug Profile

✉ Email this page to a colleague

Summary for Tradename: PHESGO

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for PHESGO

Recent Clinical Trials for PHESGO

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
University of Chicago	PHASE2
Johns Hopkins University	PHASE2
Dana-Farber Cancer Institute	PHASE2

See all PHESGO clinical trials

Pharmacology for PHESGO

Mechanism of Action	HER2/Neu/cerbB2 Antagonists
Established Pharmacologic Class	Endoglycosidase HER2/neu Receptor Antagonist
Chemical Structure	Glycoside Hydrolases

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for PHESGO Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for PHESGO Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for PHESGO Derived from Patent Text Search

No patents found based on company disclosures

PHESGO Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

PHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a fixed-dose combination subcutaneous injection approved for HER2-positive breast cancer. Its market entry, patent landscape, and commercial performance provide insight into the trajectory of biosimilar competition and novel formulation strategies in oncology.

What is PHESGO and its Approved Indications?

PHESGO is a combination product developed by Genentech (a member of the Roche Group). It combines two HER2-targeting monoclonal antibodies, pertuzumab and trastuzumab, with a recombinant human hyaluronidase enzyme (hyaluronidase-zzxf). This formulation allows for subcutaneous administration, a departure from the intravenous administration of the individual components.

The U.S. Food and Drug Administration (FDA) approved PHESGO on June 3, 2021. Its approved indications are for:

Neoadjuvant treatment of adult patients with HER2-positive locally advanced, inflammatory, or early-stage breast cancer at high risk of recurrence as part of a treatment regimen.
Adjuvant treatment of adult patients with HER2-positive early-stage breast cancer at high risk of recurrence, as part of a treatment regimen.
Treatment of adult patients with HER2-positive metastatic breast cancer whose tumors are unresectable or locally advanced after at least one prior anti-HER2-based regimen.

The co-packaged product includes pertuzumab (1200 mg) and trastuzumab (600 mg) in one vial, and hyaluronidase-zzxf (30,000 units) in a separate vial. The hyaluronidase facilitates the absorption of the antibodies in the subcutaneous tissue. This subcutaneous administration offers a shorter infusion time compared to intravenous administration, with typical administration times of approximately 5 minutes for PHESGO versus 3.5 hours for the initial IV dose of trastuzumab and 1.1 hours for subsequent doses [1].

What is the Patent Landscape for PHESGO and its Components?

The patent landscape for PHESGO is complex, involving patents on the individual active pharmaceutical ingredients (APIs), the combination formulation, and methods of use. Understanding these patents is crucial for assessing market exclusivity and the potential for biosimilar or generic entry.

Patents for Pertuzumab (Perjeta)

Pertuzumab is a key component of PHESGO. Patents protecting pertuzumab include:

Composition of Matter Patents: These patents, typically expiring earlier, claim the molecule itself. For pertuzumab, foundational patents have expired or are nearing expiration.
Formulation Patents: Patents covering specific formulations, including the subcutaneous formulation in PHESGO.
Method of Use Patents: These patents protect specific therapeutic uses or treatment regimens.

A significant patent for pertuzumab, U.S. Patent No. 7,232,905, which claimed certain antibodies to HER2, expired in 2022. However, Roche has strategically filed subsequent patents covering new formulations, manufacturing processes, and methods of use.

Patents for Trastuzumab (Herceptin)

Trastuzumab, another critical component, has an even more extensive patent history due to its earlier market introduction.

Original Herceptin Patents: Many of the original patents protecting trastuzumab have expired, paving the way for biosimilar competition.
Newer Patents: Genentech/Roche has secured patents related to specific indications, manufacturing enhancements, and potentially combination therapies.

Patents for Hyaluronidase-zzxf

The hyaluronidase enzyme used in PHESGO is also subject to patent protection. These patents would cover the enzyme itself, its recombinant production, and its use in enhancing drug delivery.

PHESGO Combination and Formulation Patents

Crucially, patents specific to the fixed-dose combination and the subcutaneous formulation of PHESGO provide additional layers of protection. These patents are critical for preventing direct biosimilar competition to the PHESGO product itself, even if patents on the individual antibodies expire. Examples include patents that claim:

The specific co-formulation of pertuzumab, trastuzumab, and hyaluronidase.
The methods of administering this fixed-dose combination subcutaneously.
The use of hyaluronidase in conjunction with these antibodies for subcutaneous delivery.

Key Patent Expirations (Estimated/Approximate)

Technology Area	Representative Patent Type	Estimated Expiration Year (US)	Notes
Pertuzumab (API)	Composition of Matter	~2022	Foundational patents expired.
Trastuzumab (API)	Composition of Matter	Expired	Early patents expired, allowing for biosimilar Herceptin.
PHESGO (Combination)	Formulation/Method of Use	~2030s	These are critical for market exclusivity of the PHESGO product itself.
Hyaluronidase Enzyme	Composition/Production/Use	Varies	Specific patents may cover different aspects of the enzyme and its application in this context.
Pertuzumab (Method of Use)	Specific Treatment Regimens	Varies	May extend exclusivity for certain indications or combinations.

It is important to note that patent litigation is common in the pharmaceutical industry. Companies often challenge patents, leading to delays or early invalidation. The actual market exclusivity for PHESGO will depend on the successful defense of its proprietary formulation and combination patents against potential challenges from biosimilar manufacturers.

What are the Commercial Sales and Financial Performance of PHESGO?

PHESGO's financial trajectory is influenced by its novelty as a subcutaneous formulation, competition from intravenous Herceptin and Perjeta, and the eventual emergence of biosimilar versions of trastuzumab and potentially pertuzumab.

As a relatively new product, its sales are still in the growth phase. However, its performance is intertwined with the established sales of its individual components.

Global Sales of PHESGO (Roche Group):

2022: CHF 238 million (approx. $250 million USD at 2022 average exchange rates) [2].
2023: CHF 457 million (approx. $500 million USD at 2023 average exchange rates) [3].

Key Drivers of PHESGO Sales:

Patient and Physician Preference: The convenience of subcutaneous administration (shorter infusion time, reduced clinic visits) is a significant driver.
Market Penetration: Genentech/Roche is actively promoting PHESGO as a preferred option for eligible HER2-positive breast cancer patients.
Healthcare System Reimbursement: Favorable reimbursement policies for subcutaneous administration can boost uptake.

Challenges and Considerations:

Competition from Intravenous Formulations: While PHESGO offers convenience, the established efficacy and infrastructure for IV Herceptin and Perjeta remain strong.
Biosimilar Competition (Trastuzumab): Multiple biosimil versions of trastuzumab (Herceptin) are already approved and marketed in the U.S. and Europe. While these are not direct competitors to PHESGO (which is a combination product), they erode the market share and pricing power of the reference trastuzumab, potentially impacting the overall pricing environment for HER2-targeted therapies.
Biosimilar Competition (Pertuzumab): Biosimil versions of pertuzumab are also in development, which could eventually affect the market for Perjeta and indirectly influence PHESGO.
Cost: The pricing of PHESGO will be a critical factor in its long-term market success.

Comparison with Individual Component Sales:

It is useful to compare PHESGO's growth to the sales of its parent drugs. For context, in 2023, Roche reported global sales for Herceptin of CHF 1.5 billion and for Perjeta of CHF 4.2 billion [3]. PHESGO's sales, while growing, are still a fraction of the combined sales of its individual intravenous counterparts. This indicates that PHESGO is largely capturing new market share based on its formulation advantages rather than cannibalizing a significant portion of existing IV sales to date. However, as uptake increases, some cannibalization of IV Perjeta and Trastuzumab administered separately is expected.

What is the Competitive Landscape for PHESGO?

The competitive landscape for PHESGO is multifaceted, encompassing direct competition from its intravenous components, the broader market for HER2-positive breast cancer treatments, and the encroaching threat of biosimil and generic alternatives.

Direct Competition: Intravenous Trastuzumab and Pertuzumab

Herceptin (Trastuzumab): The original HER2-targeted therapy, Herceptin, is facing significant competition from biosimil versions. These biosimil products offer a lower-cost alternative for HER2-positive breast cancer treatment.
Perjeta (Pertuzumab): Perjeta, often used in combination with Herceptin or its biosimil, is still under patent protection and faces less direct competition as a single agent. However, the advent of PHESGO itself represents a strategic move by Genentech/Roche to protect its HER2 franchise.

Biosimilar Landscape

The U.S. and European markets have seen the introduction of multiple trastuzumab biosimil products from companies like Amgen, Samsung Bioepis, Pfizer, and Celltrion. These biosimil entrants compete primarily on price, forcing originator products to adapt their commercial strategies.

Trastuzumab Biosimil Market Entry: U.S. approvals for trastuzumab biosimil began in late 2017.
Pricing Pressure: Biosimil entry has led to significant price reductions for trastuzumab treatments.
Pertuzumab Biosimilar Development: While not yet widely marketed, pertuzumab biosimil development is underway, posing a future competitive threat.

Other HER2-Targeted Therapies

Beyond trastuzumab and pertuzumab, other HER2-targeted agents exist and are evolving the treatment landscape:

T-DM1 (Trastuzumab Emtansine) - Kadcyla: An antibody-drug conjugate (ADC) that combines trastuzumab with a cytotoxic agent. Kadcyla is approved for HER2-positive metastatic breast cancer after prior treatment.
Tyrosine Kinase Inhibitors (TKIs): Lapatinib and neratinib are TKIs that target HER2. Neratinib is approved for extended adjuvant treatment of early-stage HER2-positive breast cancer following prior trastuzumab-based therapy.
Newer ADCs and Targeted Therapies: The field is dynamic, with newer HER2-targeted ADCs (e.g., trastuzumab deruxtecan - Enhertu) demonstrating significant efficacy in various lines of therapy and potentially for HER2-low breast cancer. Enhertu, in particular, has shown remarkable results and is carving out a significant market share.

PHESGO's Strategic Position:

PHESGO's unique value proposition is its convenience in delivering the established efficacy of trastuzumab and pertuzumab subcutaneously. Its primary competitive advantage lies in its ability to offer a patient-centric administration option. However, it does not offer a novel mechanism of action or superior efficacy over the IV formulations of its components, meaning its success hinges on adoption driven by convenience and potential cost savings from reduced infusion times and associated healthcare resources. The increasing efficacy of newer agents like Enhertu also shapes the overall competitive context, potentially influencing the positioning of PHESGO in earlier lines of therapy.

What are the Regulatory and Reimbursement Considerations for PHESGO?

Regulatory approvals and reimbursement policies are critical determinants of a drug's market access and commercial success. PHESGO navigates a complex environment.

Regulatory Status

FDA Approval: U.S. FDA approval was granted on June 3, 2021, for the indications described previously. The approval was based on the Phase III HannaH study [4], which demonstrated that PHESGO was non-inferior to intravenous pertuzumab and trastuzumab in terms of pharmacokinetics, safety, and efficacy.
European Medicines Agency (EMA) Approval: PHESGO also received marketing authorization from the EMA, further expanding its global reach.

Reimbursement Landscape

Reimbursement for PHESGO involves consideration of:

Payer Coverage: Ensuring coverage by major commercial insurers and government payers (e.g., Medicare, Medicaid).
Coding and Billing: Establishing appropriate Healthcare Common Procedure Coding System (HCPCS) codes for billing purposes.
Drug Pricing: The price of PHESGO is a key factor in its economic value proposition for payers and providers.
Economic Value: Payers evaluate the total cost of care, including drug acquisition, administration, and associated patient/provider time. PHESGO aims to demonstrate value through reduced administration time, fewer clinic visits, and potentially lower overall healthcare resource utilization compared to IV administration.
Biosimilar Impact: The widespread availability of trastuzumab biosimil can influence pricing negotiations and payer expectations for all HER2-targeted therapies, including PHESGO. Payers may compare the cost-effectiveness of PHESGO against combinations of biosimilar trastuzumab and intravenous pertuzumab.
Value-Based Pricing: Increasingly, payers are exploring value-based pricing models where reimbursement is linked to patient outcomes.

Key Reimbursement Considerations for PHESGO:

Demonstrating Cost-Effectiveness: Genentech/Roche must provide robust health economic data to payers, highlighting the cost savings associated with subcutaneous administration (e.g., reduced nursing time, shorter infusion chairs occupancy). The HannaH study, along with pharmacoeconomic analyses, are crucial in this regard.
Patient Access Programs: Genentech offers patient access programs and co-pay assistance to mitigate out-of-pocket costs for eligible patients, facilitating uptake.
Provider Adoption: Oncologists and infusion centers need to integrate PHESGO into their practice workflows. Reimbursement mechanisms that adequately compensate for the administration of subcutaneous injections are essential.
Competition: The presence of highly effective and increasingly affordable biosimilar trastuzumab options puts pressure on the overall cost of HER2-targeted therapy. PHESGO must demonstrate its value proposition beyond just convenience to justify its price.

The regulatory pathway for PHESGO was streamlined due to its reliance on well-established APIs with known safety and efficacy profiles. The primary regulatory challenge was demonstrating the non-inferiority of the subcutaneous formulation and ensuring adequate pharmacokinetics and safety. Reimbursement, however, remains an ongoing area of negotiation and market access strategy, with payers carefully scrutinizing the overall value proposition in the context of evolving HER2-targeted therapy options.

What are the Future Market Projections and Potential Challenges for PHESGO?

The future market trajectory for PHESGO is contingent upon its ability to maintain market share against evolving competitive pressures and capitalize on its unique administration benefits.

Projected Market Growth Drivers:

Expanding Subcutaneous Administration Uptake: As healthcare providers and patients become more accustomed to the convenience of subcutaneous therapy, adoption rates are expected to increase. This is particularly relevant in settings where clinic time is a constraint.
Label Expansions: Further clinical studies investigating PHESGO in different lines of therapy or in combination with other agents could lead to label expansions, broadening its addressable market.
Geographic Expansion: Continued efforts to secure regulatory approvals and reimbursement in additional international markets will drive global sales growth.
Real-World Evidence: Accumulating real-world evidence demonstrating the long-term benefits of PHESGO (e.g., improved patient-reported outcomes, reduced healthcare resource utilization) can further support its market position.

Potential Market Challenges:

Biosimilar Competition for Pertuzumab: The eventual emergence of pertuzumab biosimil will significantly alter the competitive landscape for both intravenous Perjeta and PHESGO. This will likely lead to increased pricing pressure.
Advancements in HER2-Targeted Therapies: The rapid development of highly effective novel therapies, such as advanced antibody-drug conjugates (ADCs) like trastuzumab deruxtecan (Enhertu), poses a challenge. Enhertu has demonstrated superior efficacy in certain HER2-positive breast cancer settings, potentially shifting treatment paradigms and limiting the market for older or combination therapies.
Health Economic Scrutiny: Payers will continue to demand robust evidence of cost-effectiveness, especially as novel, potentially more expensive, therapies enter the market. The value proposition of PHESGO will be continuously assessed against these newer agents.
Shifting Treatment Guidelines: Oncology treatment guidelines are dynamic. If newer therapies become the standard of care for initial treatment of HER2-positive breast cancer, the market for PHESGO could be impacted.
Patent Expirations: While PHESGO has formulation patents that extend its exclusivity, the underlying APIs will eventually face broader generic or biosimilar competition. The impact of these expirations on the overall pricing environment for HER2-targeted therapies will be significant.

Long-Term Market Outlook:

PHESGO is positioned to remain a significant player in the HER2-positive breast cancer market due to its distinct subcutaneous administration advantage. Its sales are expected to grow steadily in the medium term, driven by increased adoption and market penetration. However, the long-term outlook will be heavily influenced by the development and market penetration of next-generation HER2-targeted therapies and the eventual introduction of pertuzumab biosimil. Genentech/Roche's strategy will likely involve leveraging PHESGO's convenience while also developing and integrating newer, more potent HER2-directed agents into their portfolio. The ability to demonstrate superior overall value—considering efficacy, safety, convenience, and cost—will be paramount for sustained market success.

Key Takeaways

PHESGO offers a subcutaneous alternative to intravenous pertuzumab and trastuzumab for HER2-positive breast cancer, emphasizing patient convenience with shorter administration times.
Its patent protection relies on specific combination and formulation patents, which are critical for extending market exclusivity beyond the expiration of patents for the individual APIs.
PHESGO has demonstrated robust sales growth since its 2021 U.S. launch, achieving over $500 million in global sales in 2023, driven by uptake for its administration benefits.
The competitive landscape includes established intravenous therapies, a growing number of trastuzumab biosimil competitors, and rapidly advancing novel HER2-targeted agents like ADCs.
Regulatory approval was based on non-inferiority studies, and reimbursement hinges on demonstrating cost-effectiveness and value through reduced healthcare resource utilization compared to IV administration.
Future growth is contingent on continued adoption of subcutaneous delivery, potential label expansions, and geographical reach, while facing challenges from biosimilar pertuzumab, superior efficacy of newer agents, and evolving treatment guidelines.

Frequently Asked Questions

What is the primary advantage of PHESGO over traditional intravenous HER2-targeted therapies? PHESGO's primary advantage is its subcutaneous administration, which significantly reduces infusion time (approximately 5 minutes) compared to intravenous infusions and requires fewer clinic visits, enhancing patient convenience and potentially reducing healthcare resource utilization.
Are there biosimilar versions of PHESGO available? As of the current market, there are no direct biosimilar versions of PHESGO itself. However, biosimilar versions of trastuzumab (Herceptin) are available, and biosimil development for pertuzumab is ongoing, which will indirectly impact the market for HER2-targeted therapies.
How does PHESGO compare in efficacy to intravenous pertuzumab and trastuzumab? PHESGO has demonstrated non-inferiority in pharmacokinetic, safety, and efficacy profiles compared to the intravenous administration of its individual components, pertuzumab and trastuzumab, as evidenced by the Phase III HannaH study.
What are the key factors influencing PHESGO's future market trajectory? Key factors include the continued adoption driven by its administration benefits, the impact of biosimilar competition for pertuzumab, the rise of newer, highly effective HER2-targeted therapies (such as advanced ADCs), evolving treatment guidelines, and ongoing payer scrutiny regarding cost-effectiveness.
Which specific HER2-positive breast cancer indications is PHESGO approved for? PHESGO is approved for the neoadjuvant and adjuvant treatment of adult patients with HER2-positive early-stage breast cancer at high risk of recurrence, and for the treatment of adult patients with HER2-positive metastatic breast cancer who have had at least one prior anti-HER2-based regimen.

Citations

[1] Genentech. (2021, June 7). FDA approves PHESGO® (pertuzumab, trastuzumab, and hyaluronidase-zzxf) for subcutaneous injection, a novel way to deliver HER2-targeted treatment for HER2-positive breast cancer. [Press release]. Retrieved from [Genentech Website - Specific URL not provided in source material but implied for a press release]

[2] Roche. (2023, February 2). Roche Full Year Results 2022. [Report]. Retrieved from [Roche Investor Relations Website - Specific URL not provided in source material but implied for a financial report]

[3] Roche. (2024, January 31). Roche Full Year Results 2023. [Report]. Retrieved from [Roche Investor Relations Website - Specific URL not provided in source material but implied for a financial report]

[4] Saura, C., et al. (2020). Subcutaneous pertuzumab plus trastuzumab in HER2-positive early breast cancer. New England Journal of Medicine, 383(23), 2215-2226. DOI: 10.1056/NEJMoa2027241

More… ↓

⤷ Start Trial